SCHEMBL13288955

SCHEMBL13288955

Cc1cnn2c(NCCCCNC(=O)C(C)Cc3ccccc3)cc(-c3ccccc3Cl)nc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 6/20 0.45
▸ CDK2 P24941 5/20 0.45
▸ CYP3A4 P08684 4/20 0.41
▸ TSHR P16473 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.38
▸ HPGD P15428 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ CDK7 P50613 2/20 0.37
▸ CCNT1 O60563 1/20 0.37
▸ CDK1 P06493 1/20 0.37
▸ CDK4 P11802 1/20 0.37
▸ CCNB1 P14635 1/20 0.37
▸ CCND1 P24385 1/20 0.37
▸ CCNE1 P24864 1/20 0.37
▸ CDK8 P49336 1/20 0.37
▸ CDK9 P50750 1/20 0.37
▸ CCNH P51946 1/20 0.37
▸ MNAT1 P51948 1/20 0.37
▸ CDK6 Q00534 1/20 0.37
▸ CDK5 Q00535 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13120123 0.91 CDK2 (0.56) GSK3BCDK2CYP3A4TSHRCCNE1
SCHEMBL13120042 0.89 CDK2 (0.56) GSK3BCDK2CYP3A4TSHRCCNE1
SCHEMBL13289193 0.86 GSK3B (0.47) GSK3BCDK2ALDH1A1HPGDMEN1
SCHEMBL13288688 0.86 MAPT (0.45) GSK3BCDK2ALDH1A1LMNAMEN1
SCHEMBL13120254 0.86 CDK2 (0.58) GSK3BCDK2CYP3A4TSHRCCNE1
SCHEMBL13288841 0.85 GSK3B (0.47) GSK3BCDK2ALDH1A1HPGDLMNA
SCHEMBL14545258 0.81 GSK3B (0.46) GSK3BCDK2ALDH1A1HPGDMEN1
SCHEMBL13305640 0.81 CDK2 (0.54) GSK3BCDK2CYP3A4ALDH1A1HPGD
SCHEMBL13289249 0.81 GSK3B (0.46) GSK3BCDK2ALDH1A1HPGDMEN1
SCHEMBL13119468 0.79 CDK2 (0.66) GSK3BCDK2CYP3A4ALDH1A1CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194058-A1 Pyrazolopyrimidines suitable for the treatment of cancer diseases SCHERING CORPORATION (US) 2010-06-09 — — EP disclosed
Send feedback